Changes in use of preventive medications after assessment of chest pain by coronary computed tomography angiography: A meta-analysis
- PMID: 38262852
- DOI: 10.1016/j.jcct.2024.01.006
Changes in use of preventive medications after assessment of chest pain by coronary computed tomography angiography: A meta-analysis
Abstract
Background: Coronary computed tomography angiogram (CCTA) is a crucial tool for diagnosing CAD, but its impact on altering preventive medications is not well-documented. This systematic review aimed to compare changes in aspirin and statin therapy following CCTA and functional stress testing in patients with suspected CAD, and in those underwent CCTA when stratified by the presence/absence of plaque.
Results: Eight studies involving 42,812 CCTA patients and 64,118 cardiac stress testing patients were analyzed. Compared to functional testing, CCTA led to 66 % more changes in statin therapy (pooled RR, 95 % CI [1.28-2.15]) and a 74 % increase in aspirin prescriptions (pooled RR, 95 % CI [1.34-2.26]). For medication modifications based on CCTA results, 13 studies (47,112 patients with statin data) and 11 studies (12,089 patients with aspirin data) were included. Patients with any plaque on CCTA were five times more likely to use or intensify statins compared to those without CAD (pooled RR, 5.40, 95 % CI [4.16-7.00]). Significant heterogeneity remained, which decreased when stratified by diabetes rates. Aspirin use increased eightfold after plaque detection (pooled RR, 8.94 [95 % CI, 4.21-19.01]), especially with obstructive plaque findings (pooled RR, 9.41, 95 % CI [2.80-39.02]).
Conclusion: In conclusion, CCTA resulted in higher changes in statin and aspirin therapy compared to cardiac stress testing. Detection of plaque by CCTA significantly increased statin and aspirin therapy.
Keywords: Aspirin; Cardiac stress testing; Chest pain; Coronary computed tomography angiogram; Statin.
Copyright © 2024 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Rhanderson Cardoso has received research support for Cleerly Inc. Dr. Blankstein has received research support from Amgen Inc and Novartis Inc, and has served as a consultant for Caristo Inc, Elucid Inc, Hearflow Inc, an Nanox AI. The other authors have no relevant disclosures to report.
Similar articles
-
Potential for coronary CT angiography to tailor medical therapy beyond preventive guideline-based recommendations: insights from the ROMICAT I trial.J Cardiovasc Comput Tomogr. 2015 May-Jun;9(3):193-201. doi: 10.1016/j.jcct.2015.02.006. Epub 2015 Feb 18. J Cardiovasc Comput Tomogr. 2015. PMID: 25846248 Free PMC article. Clinical Trial.
-
Changes in preventive medical therapies and CV risk factors after CT angiography.JACC Cardiovasc Imaging. 2013 May;6(5):574-81. doi: 10.1016/j.jcmg.2012.11.016. Epub 2013 Apr 10. JACC Cardiovasc Imaging. 2013. PMID: 23582355
-
Coronary artery disease detected by coronary computed tomographic angiography is associated with intensification of preventive medical therapy and lower low-density lipoprotein cholesterol.Circ Cardiovasc Imaging. 2014 Jul;7(4):629-38. doi: 10.1161/CIRCIMAGING.113.001564. Epub 2014 Jun 6. Circ Cardiovasc Imaging. 2014. PMID: 24906356
-
Bridging Prevention and Imaging: The Influence of Statins on CAC and CCTA Findings.Curr Atheroscler Rep. 2025 Apr 8;27(1):50. doi: 10.1007/s11883-025-01287-x. Curr Atheroscler Rep. 2025. PMID: 40198377 Review.
-
Nonobstructive Coronary Artery Disease by Coronary CT Angiography Improves Risk Stratification and Allocation of Statin Therapy.JACC Cardiovasc Imaging. 2017 Sep;10(9):1031-1038. doi: 10.1016/j.jcmg.2016.10.022. Epub 2017 Mar 15. JACC Cardiovasc Imaging. 2017. PMID: 28330658 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous